Literature DB >> 20181770

Re-visiting Luck's classification: a histological analysis of Dupuytren's disease.

W L Lam1, J M Rawlins, R O S Karoo, I Naylor, D T Sharpe.   

Abstract

Luck (1959) described a histological staging system for Dupuytren's disease, classifying the disease into three stages. Previous biochemical and immunochemical studies have detailed the decrease in type III/I collagen ratio with disease progression. Herovici (1963) described a histological stain that produced a differential red/purple and blue colour for type I and III collagen respectively. We stained 15 specimens of Dupuytren's disease and quantified the different collagen types in each using computer analysis. We found a corresponding decrease in the amount of type III collagen as a percentage of the total collagen with disease progression: stage I range 35-49% (mean 38%); stage 2 range 21-33% (mean 27%) and stage 3 range 11-19% (mean 14%). We propose a new staging system based on the relative amount of type III collagen, where stage 1: >35%, stage 2: >20% and <35%, and stage 3: <20%.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20181770     DOI: 10.1177/1753193410362848

Source DB:  PubMed          Journal:  J Hand Surg Eur Vol        ISSN: 0266-7681


  12 in total

Review 1.  Scientific understanding and clinical management of Dupuytren disease.

Authors:  Barbara Shih; Ardeshir Bayat
Journal:  Nat Rev Rheumatol       Date:  2010-11-09       Impact factor: 20.543

2.  Effect of nanoparticle-mediated delivery of SFRP4 siRNA for treating Dupuytren disease.

Authors:  Rujue Jin; Weigang Zhu; Jiajun Xu; Jianhui Gu; Aidong Deng
Journal:  Gene Ther       Date:  2022-03-28       Impact factor: 5.250

3.  Identification of histological patterns in clinically affected and unaffected palm regions in dupuytren's disease.

Authors:  Camilo-Andrés Alfonso-Rodríguez; Ingrid Garzón; Juan Garrido-Gómez; Ana-Celeste-Ximenes Oliveira; Miguel-Ángel Martín-Piedra; Giuseppe Scionti; Víctor Carriel; Pedro Hernández-Cortés; Antonio Campos; Miguel Alaminos
Journal:  PLoS One       Date:  2014-11-07       Impact factor: 3.240

4.  Anti-Tumour Necrosis Factor Therapy for Dupuytren's Disease: A Randomised Dose Response Proof of Concept Phase 2a Clinical Trial.

Authors:  Jagdeep Nanchahal; Catherine Ball; Dominique Davidson; Lynn Williams; William Sones; Fiona E McCann; Marisa Cabrita; Jennifer Swettenham; Neil J Cahoon; Bethan Copsey; E Anne Francis; Peter C Taylor; Joanna Black; Vicki S Barber; Susan Dutton; Marc Feldmann; Sarah E Lamb
Journal:  EBioMedicine       Date:  2018-07-06       Impact factor: 8.143

5.  Association between Stenosing Tenosynovitis and Dupuytren's Contracture in the Hand.

Authors:  Kai Yang; Michael Gehring; Savo Bou Zein Eddine; Patrick Hettinger
Journal:  Plast Reconstr Surg Glob Open       Date:  2019-01-11

6.  Matrix and cell phenotype differences in Dupuytren's disease.

Authors:  Marike M van Beuge; Evert-Jan P M Ten Dam; Paul M N Werker; Ruud A Bank
Journal:  Fibrogenesis Tissue Repair       Date:  2016-06-29

Review 7.  Systematic review of non-surgical treatments for early dupuytren's disease.

Authors:  Catherine Ball; David Izadi; Liaquat Suleman Verjee; James Chan; Jagdeep Nanchahal
Journal:  BMC Musculoskelet Disord       Date:  2016-08-15       Impact factor: 2.362

8.  Efficacy and safety of collagenase clostridium histolyticum for Dupuytren disease nodules: a randomized controlled trial.

Authors:  Bronier Costas; Stephen Coleman; Greg Kaufman; Robert James; Brian Cohen; R Glenn Gaston
Journal:  BMC Musculoskelet Disord       Date:  2017-08-30       Impact factor: 2.362

9.  A Genome-wide Association Study of Dupuytren Disease Reveals 17 Additional Variants Implicated in Fibrosis.

Authors:  Michael Ng; Dipti Thakkar; Lorraine Southam; Paul Werker; Roel Ophoff; Kerstin Becker; Michael Nothnagel; Andre Franke; Peter Nürnberg; Ana Isabel Espirito-Santo; David Izadi; Hans Christian Hennies; Jagdeep Nanchahal; Eleftheria Zeggini; Dominic Furniss
Journal:  Am J Hum Genet       Date:  2017-09-07       Impact factor: 11.025

Review 10.  Cytokine Targeted Therapy for Dupuytren's Disease.

Authors:  Latha Satish
Journal:  EBioMedicine       Date:  2018-07-18       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.